BRWM
CASC

B. Riley Wealth Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

B. Riley Wealth Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-833
Closed -$18K – 930
2015
Q2 		$18K Buy
+833
New +$13.2K 0.01% 634

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

B. Riley Wealth Management's CASC Position: Q3 2015 in Review

B. Riley Wealth Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2015, closing a stake of 833 shares — an estimated $18K sold.

B. Riley Wealth Management first reported a position in CASC in Q2 2015 and held it in 1 quarter. The position peaked at $18K in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q3 2015.

  • B. Riley Wealth Management reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • B. Riley Wealth Management sold 833 Cascadian Therapeutics, Inc. shares in Q3 2015, an estimated $18K.
  • B. Riley Wealth Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • B. Riley Wealth Management's Cascadian Therapeutics, Inc. position peaked at $18K in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2015.

Based on B. Riley Wealth Management's 13F filing for Q3 2015, filed 13 Oct 2015.